Region: France

AI and blockchain are helping to transform IP market, says Erich Spangenberg

IAM speaks to IPwe founder about the new patterns of patent deal-making made possible by developing technologies

30 May 2022

Five key trends shaping the patent market in France

The arrival of the UPC, a sharp uptick in the number of FRAND disputes and a boost for efforts to promote IP culture, in particular among SMEs, are all having a big impact, writes Magda Voltolini

04 May 2022

Nokia, Oppo dig in for big decisions in global patent battle

The litigation state of play across nine jurisdictions in Europe and Asia as the two parties compete for leverage in re-negotiation of SEP deal

15 April 2022

Sanofi scores $300 million in unusual royalty deal

Deal announced by French pharma giant this week is highly distinctive, but also reflects several recent trends in the booming drug revenue market

17 March 2022

Revealed: first Chinese target of ZTE's new SEP licensing push

Court documents show that ZTE has filed a patent suit against Tinno Mobile, the Shenzhen-based company that owns French smartphone brand Wiko

08 December 2021

Data monetisation drives Sanofi’s $180 million investment in AI biotech Owkin

The deal shows how privacy and silo barriers to the commercialisation of information are being overcome

29 November 2021

mRNA IP will be hot property beyond the pandemic

$3.2 billion Sanofi deal is unlikely to be the last as Big Pharma seeks to consolidate its position in the cutting-edge field

12 August 2021

Nokia launches patent litigation against Oppo across Europe and Asia

The two companies have been re-negotiating a 2018 licensing deal covering wireless technologies

08 July 2021

French SPC rulings give first signs of Royalty Pharma’s impact

Paris Court of Appeal turns down three appeals over supplementary protection certificate rejections

12 April 2021

Record French damages award is a good sign for pharma patentees

Recent decision to award Eli Lilly a preliminary injunction and damages in case against a generic company demonstrates an increasingly pro-rights holder approach on the part of a key French court

08 February 2021

Unlock unlimited access to all IAM content